Alcatel-Lucent Enterprise Hosts First Global Virtual Conference for Partners
1.2.2021 12:00:00 EET | Business Wire | Press release
Alcatel-Lucent Enterprise , a leading digital-age networking, communications and cloud solutions provider, is hosting its Connex21 global partner conference virtually between February 1-4, 2021. It is the latest in an extensive program of virtual events, after the company adapted its priorities to keep employees safe and maintain business continuity for partners and customers.
Over 2,100 Alcatel-Lucent Enterprise partners and industry analysts from all over the world have registered to attend the summit. Under the theme ‘Build 2 Last’, Connex21 will feature speakers including CEO Jack Chen and Rukmini Glanard, Executive Vice President Global Sales, Services and Marketing.
Jack and Rukmini will join other Alcatel-Lucent Enterprise business leaders to outline the company’s 2021 strategy, discuss core business objectives, explain the product roadmap, and explore the growth opportunities this year poses for the business and its international partners.
“Last year was very difficult for every one of us,” comments Jack Chen, CEO of Alcatel-Lucent Enterprise. “The current situation has changed the way we work, and some of these changes will become permanent. This crisis has highlighted the critical need for digital transformation. Digital technology is enabling businesses to generate revenue, retain staff, and survive in challenging conditions. Technology is helping us all to adapt and find ways to grow.”
Over the course of Connex21, executives at the company will host dedicated sessions to demonstrate the impact its innovations are having in vertical industries across the globe. Product specialists will present the Alcatel-Lucent Enterprise roadmap for new solutions designed to support partners in solving business issues and driving growth for customers. The business will also outline its plan to support its partner community in 2021 with Cloud, Network and Communications solutions designed for critical verticals such as Transportation, Healthcare, Education, Government and Hospitality.
“Alcatel-Lucent Enterprise has a long history of evolving with the times,” says Jack Chen. “We’ve had to adapt to address the needs of the enterprise successfully for over 100 years. Versatility is in our DNA and originates from our ability to embrace innovation. Our solutions help businesses grow, irrespective of the market conditions. Our partners believe in our vision to help organisations grow through innovation and, together, we work tirelessly to achieve it. We want to continue to build great relationships and solutions that will last long into the future.”
Alcatel-Lucent Enterprise has a strong ecosystem of 2,900 direct business partners all over the world. This helps the company achieve an effective international reach, with a local focus, for over 830,000 customers in 100 countries around the world.
About Alcatel-Lucent Enterprise
Alcatel-Lucent Enterprise delivers the customised technology experiences enterprises need to make everything connect.
ALE provides digital-age networking, communications and cloud solutions tailored to ensure customers’ success, with flexible business models in the cloud, on premises, and hybrid. All solutions have built-in security and limited environmental impact.
Over 100 years of innovation have made Alcatel-Lucent Enterprise a trusted advisor to more than 830,000 customers in 100 countries around the world.
The privately-owned company with headquarters in France has over 2,900 direct business partners worldwide, achieving an effective global reach with a local focus.
For more information: www.al-enterprise.com .
LinkedIn , Facebook , Twitter , Instagram .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005157/en/
Contact information
UK Press
Lisa McGauley
lisa@fox.agency
Global Press
Carine Bowen
press@al-enterprise.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom